# US 2021/0278411 A1 · Lectin-based diagnostics of cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0278411 A1
- Document ID: US20210278411A1
- Status: Published application
- Kind: A1
- Application number: 16/318,035
- Filed: 2017-07-14
- Published: 2021-09-09
- Earliest claimed: 2016-07-14
- Assignees: Kaivogen Oy
- Applicants: Kaivogen Oy
- Inventors: Kamlesh GIDWANI; Kim PETTERSSON; Henna KEKKI
- Web page: https://patentgrep.com/patent/US20210278411A1

## CPC

- G01N 33/57525: of the liver or pancreas
- G01N 33/57515: of the breast
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/57555: of the prostate
- G01N 2333/4724: Lectins
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2400/00: Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to non-invasive diagnostics of cancers, such as breast cancer, colorectal cancer, pancreatic cancer and prostate cancer, on the basis of altered glycosylation patterns of cancer-associated biomarkers.

## Claims

### Claim 1

A method of determining a prostate cancer disease state in a subject, said method comprising:
assaying a sample obtained from said a subject for detecting a level of a PSA glycoform which binds to macrophage galactose-type lectin (MGL);
comparing a detected level of said lectin-binding PSA glycoform in said sample with that of a control sample or a predetermined threshold value; and
determining a prostate cancer disease state for said subject based on said comparison.

### Claim 2 (depends on 1)

The method according to claim 1, comprising:
assaying a sample obtained from said subject for detecting a level of a PSA protein antigen as a biomarker; and
comparing the detected level of said one or more biomarker in said sample with that of a control sample or a predetermined threshold value.

### Claim 3

A method of determining a colorectal cancer disease state in a subject, said method comprising:
assaying a sample obtained from a subject for detecting a level of a CEA glycoform which binds to one or more lectins selected from a group consisting of mannose binding lectin (MBL), Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) and MGL;
comparing the detected level of said lectin-binding CEA glycoform in said sample with that of a control sample or a predetermined threshold value, and
determining a colorectal cancer disease state for said subject based on said comparison.

### Claim 4 (depends on 3)

The method according to claim 3, comprising:
assaying a binding of CEA to MBL and DC-SIGN, MBL and MGL, DC-SIGN and MGL, or MBL, DC-SIGN and MGL.

### Claim 5 (depends on 3)

The method according to claim 3, comprising:
assaying a sample obtained from said subject for detecting a level of a CEA protein antigen as a biomarker; and
comparing the detected level of said one or more biomarker in said sample with that of a control sample or a predetermined threshold value.

### Claim 6

A method of determining a pancreatic cancer disease state in a subject, said method comprising:
assaying a sample obtained from a subject for detecting a level of a CA19-9 glycoform which binds to DC-SIGN;
comparing the detected level of said lectin-binding CA19-9 glycoform in said sample with that of a control sample or a predetermined threshold value; and
determining a prostate cancer disease state for said subject based on said comparison.

### Claim 7 (depends on 6)

The method according to claim 6, comprising:
assaying a sample obtained from said subject for detecting a level of a CA19-9 protein antigen as a biomarker; and
comparing the detected level of said one or more biomarker in said sample with that of a control sample or a predetermined threshold value.

### Claim 8

A method of determining a breast cancer disease state in a subject, said method comprising:
assaying a sample obtained from a subject for detecting a level of CA15-3 glycoform which binds to one or more lectins selected form the group consisting of MGL and wheat germ agglutin (WGA);
comparing the detected level of said lectin-binding glycoform of CA15-3 in said sample with that of a control sample or a predetermined threshold value; and
determining a breast cancer disease state for said subject based on said comparison.

### Claim 9 (depends on 8)

The method according to claim 8, comprising:
assaying a sample obtained from said sample for detecting a level of one or more further CA15-3 glycoforms which bind a lectin selected from the group consisting of DSL and Gal4; and
comparing the detected level of said one or more further lectin-binding glycoforms in said sample with that of a control sample or a predetermined threshold value.

### Claim 10 (depends on 8)

The method according to claim 8, comprising:
assaying a sample obtained from said subject for detecting a level of one or more known biomarkers selected from the group consisting of CA15-3, CA125, and CEA; and
comparing the detected level of said one or more biomarker in said sample with that of a control sample or a predetermined threshold value.

### Claim 11 (depends on 1)

The method according to claim 1, comprising:
comparing an increase in the detected level in said sample with that of a control sample or a predetermined threshold value to indicate that said subject has or is at risk of having said cancer.

### Claim 12 (depends on 1)

The method according to claim 1, comprising:
screening, diagnosing, prognosing, or monitoring said cancer.

### Claim 13 (depends on 12)

The method according to claim 12, comprising:
monitoring for onset of said cancer, monitoring any change in risk of having or developing said cancer, monitoring response to treatment, monitoring relapse of said cancer, or monitoring recurrence of said cancer.

### Claim 14 (depends on 1)

The method according to claim 1, wherein assaying for detecting the level of said one or more lectin-binding glycoforms of a biomarker is carried out by a binding assay comprising:
subjecting said sample to an antibody specific for said biomarker in order to capture the biomarker contained in the sample,
subjecting said captured biomarker to one or more lectins; and
measuring a level of binding of said captured biomarker to said one or more lectins with aid of a detectable signal.

### Claim 15 (depends on 1)

The method according to claim 1, wherein assaying for detecting the level of said one or more lectin-binding glycoforms of a biomarker is carried out by a binding assay comprising:
subjecting said sample to one or more lectins in order to capture one or more lectin-binding glycoforms of said biomarker contained in the sample;
subjecting said captured biomarker to an antibody specific for the biomarker; and
measuring a level of binding of said captured biomarker to an antibody specific for the biomarker with aid of a detectable signal.

### Claim 16 (depends on 14)

The method according to claim 14, wherein either said lectin or said antibody is immobilized on a nanoparticle.

### Claim 17 (depends on 1)

The method according to claim 1, wherein said sample is selected from the group consisting of urine, blood, serum, plasma, peritoneal cavity fluid, and tissue samples.

### Claim 18

A kit for determining a prostate cancer disease state in a subject, the kit, comprising:
a PSA-binding agent and MGL;
wherein either said PSA-binding agent or said MGL includes a detectable label.

### Claim 19 (depends on 18)

The kit according to claim 18, comprising:
a further PSA-binding agent.

### Claim 20

A kit for determining a colorectal cancer disease state in a subject, the kit, comprising:
a CEA-binding agent and one or more lectins selected from the group consisting of MBL, DC-SIGN and MGL;
wherein either said CEA-binding agent or said lectin includes a detectable label.

### Claim 21 (depends on 20)

The kit according to claim 20 comprising:
MBL and DC-SIGN, MBL and MGL, DC-SIGN and MGL, or MBL, DC-SIGN and MGL.

### Claim 22 (depends on 20)

The kit according to claim 20, comprising:
a CEA-binding agent.

### Claim 23

A kit for determining a pancreatic cancer disease state in a subject, the kit, comprising:
a CA19-9-binding agent and DC-SIGN;
wherein either said CA19-9-binding agent or said DC-SIGN includes a detectable label.

### Claim 24 (depends on 23)

The kit according to claim 23, comprising:
CA-19-9-binding agent.

### Claim 25

A kit for determining a breast cancer disease state in a subject, the kit comprising:
a CA15-3-binding agent; and
one or more lectins selected from the group consisting of MGL and WGA;
wherein either said CA15-3-binding agent or said one or more lectins includes a detectable label.

### Claim 26 (depends on 25)

The kit according to claim 25, comprising:
a CA-15-3-binding agent.

### Claim 27 (depends on 18)

The kit according to claim 18, comprising:
one or more lectins selected from the group consisting of SBA, SNA, PNA, MAA II, AAL, UEA, PHA-E, RCA, WGA, WFA, PSA, VVL, TJA-II, DSL, HPA, MGL, DC-SIGN, MMR, MBL, Siglec-2, Siglec-3, Siglec-5, Siglec-9, Siglec-10, Siglec-11, Galectin-3, Galectin-4, E-selectin, DSL and Gal4.

### Claim 28 (depends on 18)

The kit according to claim 18, wherein said lectin is immobilized on a nanoparticle.

### Claim 29 (depends on 28)

The kit according to claim 28, wherein all dimensions of said nanoparticle are less than about 1000 nm, about 500 nm or less, about 100 nm or less, or about 50 nm or less.

### Claim 30 (depends on 29)

The kit according to claim 29, wherein said nanoparticle is selected from the group consisting of protein nanoparticles, mineral nanoparticles, glass nanoparticles, nanoparticle crystals, metal nanoparticles, plastic nanoparticles, polystyrene nanoparticles, poly(ethylene glycol) nanoparticles, polyethylene nanoparticles, poly(acrylic acid) nanoparticles, poly(methyl methacrylate) nanoparticles, polysaccharide nanoparticles, colloidal gold nanoparticles, silver nanoparticles, quantum dots, carbon nanoparticles, porous silica nanoparticles, and liposomes.

### Claim 31 (depends on 29)

The method or kit according to claim 29, wherein said nanoparticle is doped with a lanthanide chelate.

### Claim 32

A method for determining a prostate cancer disease state in a subject, the method comprising:
assaying a sample obtained from said subject for a level of PSA glycoform which binds to MGL.

### Claim 33

A method for determining a colorectal cancer disease state in a subject, the method comprising:
assaying a sample obtained from said subject for a level of CEA glycoform which binds MBL, DC-SIGN and/or MGL.

### Claim 34

A method for determining a pancreatic cancer disease state in a subject, the method comprising:
assaying a sample obtained from said subject for a level of CA19-9 glycoform which binds to DC-SIGN.

### Claim 35

A method for determining a breast cancer disease state in a subject, the method comprising:
assaying a sample obtained from said subject for a level of CA15-3 glycoform which binds to MGL, WGA, DSL, and/or Gal4, each alone or in any combination thereof.

### Claim 36 (depends on 32)

The method according to claim 32, comprising:
immobilizing the lectin on a nanoparticle or labelling the lectin with a detectable label.

### Claim 37 (depends on 32)

The method according to claim 32 comprising:
screening, diagnosing, prognosing and/or monitoring said cancer in a subject.
